secwatch / observer
8-K filed January 2, 2026, 6:59 PM ET ticker IGC CIK 0001326205
other confidence high sentiment neutral materiality 0.40

IGC Pharma changes fiscal year-end from March 31 to December 31, effective 2025

IGC Pharma, Inc.

item 5.03

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001185185-26-000010
form_type
8-K
ticker
IGC
cik
0001326205
company_name
IGC Pharma, Inc.
filed_at
2026-01-02T23:59:59+00:00
discovered_at
2026-05-14T18:02:34.810945+00:00
generated_at
2026-05-16T11:47:11.250500+00:00
sec_items
["5.03"]
event_type
other
sentiment
neutral
materiality_score
0.4
calibrated_materiality_score
0.4
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001185185-26-000010
json_url
https://secwatch.observer/filing/0001185185-26-000010.json
markdown_url
https://secwatch.observer/filing/0001185185-26-000010.md
text_url
https://secwatch.observer/filing/0001185185-26-000010.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/0001185185-26-000010-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1326205/000118518526000010/igc8k010226.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

aff8432607a99073361bcfebc78df70aea9fa910

IGC Pharma, Inc.: Changed fiscal year-end from March 31 to December 31 (effective 2025-12-31).

the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

SCYX

SCYNEXIS effects 1:8 reverse stock split; authorized shares cut to 18.75M

SCYNEXIS INC May 29, 2026, 4:01 PM ET other Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03 same event type: other similar materiality

This filing

the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.

Comparable filing

On May 28, 2026, SCYNEXIS, Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”), to effect a one-for-eight (1:8) reverse stock split of its outstanding common stock (the “Reverse Stock Split”) and a reduction in the total number of authorized shares of its common stock from 150,000,000 to 18,750,000, effective as of May 29, 2026 (the “Share Reduction”).

Filing page SEC filing

RLMD

Relmada increases authorized common shares to 200M; stockholders approve 2021 Plan amendment

RELMADA THERAPEUTICS, INC. May 28, 2026, 4:59 PM ET other Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03 same event type: other similar materiality

This filing

the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.

Comparable filing

On May 28, 2026, Relmada Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 200,000,000 shares (the “ Charter Amendment ”).

Filing page SEC filing

PGNY

Progyny shareholders approve elimination of supermajority voting requirements

Progyny, Inc. May 27, 2026, 9:13 AM ET other Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03 same event type: other similar materiality

This filing

the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.

Comparable filing

Progyny, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. At the Annual Meeting, the Company’s stockholders approved certain amendments (the “Charter Amendments”) to the Company’s Certificate of Incorporation. As further described in Proposals 4 and 5 of the Company’s definitive proxy statement filed on April 10, 2026 (the “Proxy Statement”), the Charter Amendments (a) eliminate certain supermajority voting requirements (the “Supermajority Amendments”), and (b) eliminate the default supermajority voting requirement concerning certain business combinations. The Charter Amendments became effective upon the filing of a Certificate of Amendment (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware on May 21, 2026.

Filing page SEC filing

T

AT&T annual meeting elects directors, approves incentive and exculpation amendment

AT&T INC. May 20, 2026, 5:05 PM ET other Items 5.02, 5.07, 5.03, 9.01

same fact type: governance_change same SEC item: 5.03 same event type: other similar materiality

This filing

the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.

Comparable filing

On May 15, 2026, the Company filed a Certificate of Amendment with the Secretary of State of Delaware to effect the Exculpation Amendment.

Filing page SEC filing

BAX

Baxter shareholders approve charter amendment and incentive plan; board adopts new executive severance plan

BAXTER INTERNATIONAL INC May 8, 2026, 7:59 PM ET other Items 5.02, 5.07, 5.03, 9.01

same fact type: governance_change same SEC item: 5.03 same event type: other similar materiality

This filing

the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.

Comparable filing

the Board approved a corresponding amendment and restatement of the Company’s Amended and Restated Bylaws (the “Amended Bylaws”) reflecting that the number of directors on the Board shall not be less than seven nor more than twelve

Filing page SEC filing

KGS

Kodiak shareholders approve board declassification and supermajority removal

Kodiak Gas Services, Inc. May 7, 2026, 7:59 PM ET other Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03 same event type: other similar materiality

This filing

the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.

Comparable filing

At the 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of Kodiak Gas Services, Inc. (the “Company”) held on May 7, 2026, the Company’s shareholders approved certain amendments (the “Charter Amendments”) to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to (i) phase in declassification of the Board of Directors (the “Board”) and (ii) eliminate certain supermajority voting requirements and other obsolete provisions.

Filing page SEC filing

SCHW

Charles Schwab files Certificate of Elimination for Series I Preferred Stock

SCHWAB CHARLES CORP June 1, 2026, 5:00 PM ET other Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03 same event type: other

This filing

the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.

Comparable filing

On June 1, 2026, The Charles Schwab Corporation (the “Company”) filed a Certificate of Elimination with the Secretary of State of the State of Delaware with respect to the Company’s 4.000% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series I (“Series I Preferred Stock”), which, effective upon filing, eliminated from the Company’s Fifth Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations for the Series I Preferred Stock.

Filing page SEC filing

OPLN

OPENLANE eliminates Series A Convertible Preferred Stock from charter

OPENLANE, Inc. May 29, 2026, 1:57 PM ET other Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03 same event type: other

This filing

the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.

Comparable filing

On May 29, 2026, OPENLANE, Inc. (the “Company”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware effecting the elimination of the Certificate of Designations relating to the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”) previously filed by the Company with the Secretary of State of the State of Delaware on June 9, 2020.

Filing page SEC filing

Source: SEC EDGAR
accession 0001185185-26-000010
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.